

Electronic Acknowledgement Receipt

EFS ID:	6285044
Application Number:	10539385
International Application Number:	
Confirmation Number:	4857
Title of Invention:	BENZAEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
First Named Inventor/Applicant Name:	Sanjeet Sehmi
Customer Number:	23347
Filer:	Duke M. Fitch/Mary Fenerty
Filer Authorized By:	Duke M. Fitch
Attorney Docket Number:	P33159USW
Receipt Date:	19-OCT-2009
Filing Date:	16-JUN-2005
Time Stamp:	14:43:13
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$810
RAM confirmation Number	807
Deposit Account	192570
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	RCE_Transmittal.pdf	95164	no	1
			cc916da11084fd31e26f27a5e4e3f81ce384884		

Warnings:

This is not a USPTO supplied RCE SB30 form.

Information:

2		Information_Disclosure_Statement_and_1449.pdf	263722	yes	3
			4a3308d65f909ab658ba0a97266d0bddc216370d		

Multipart Description/PDF files in .zip description

	Document Description		Start	End
	Transmittal Letter		1	1
	Information Disclosure Statement (IDS) Filed (SB/08)		2	3

Warnings:

Information:

3	Foreign Reference	1WO9605194A1.pdf	5789360	no	154
			c5197459b83ca9870a20dddc81fa7a089fa4adcd		

Warnings:

Information:

4	Foreign Reference	2WO2004058682A1_part_1.pdf	16171064	no	491
			a52f91e898a0327de07de57268153f3dec20d4b6		

Warnings:

Information:

5	Foreign Reference	2WO2004058682A1_part_2.pdf	12668023	no	491
			87d029559353b744da6192f2d1ad407e33c5d996		

Warnings:

Information:

6	Foreign Reference	3WO2005014479A2.pdf	1168787	no	28
			f7959c1e83f0782774830059e5f8f4bbcd1d264f		

Warnings:

Information:

7	Foreign Reference	4WO2005039591A1.pdf	2113209	no	43
			6f4443db6dc3a417a15a4cccd60213f6296d6c8c		
Warnings:					
Information:					
8	Foreign Reference	5WO2005058328A1.pdf	2938402	no	66
			89f1c6199f5ede0736049832d5598dbc3c7f0176		
Warnings:					
Information:					
9	Foreign Reference	6CA2197789.pdf	5373828	no	151
			9ea06d5ef619968f39ce8cfbd4b65fcaa60f2cf8		
Warnings:					
Information:					
10	Foreign Reference	7EP0612741B1.pdf	3860319	no	95
			2aab6fc07268b32d1fca05f6e9a36bed89971daa		
Warnings:					
Information:					
11	NPL Documents	8Medhurst_BiochemPharmacol_2007.pdf	592134	no	13
			f04c41919bcb4433c637f203b47f98ebd3afc559		
Warnings:					
Information:					
12	NPL Documents	9Southam_Psychoph_2009.pdf	286856	no	12
			d57b70192422b3ffc91fede5e09f4883354ed7fb		
Warnings:					
Information:					
13	NPL Documents	10Medhurst_JPharmExpTher_2007.pdf	570693	no	14
			afc52a0de3fa383b99def7170aa3eb92745205bb		
Warnings:					
Information:					
14	NPL Documents	11Medhurst_Pain_2008.pdf	411907	no	9
			f713ccfd5b18cd5ddf5c1c45a2587a32f7a56f376		
Warnings:					
Information:					
15	NPL Documents	12Perez-Garcia_Psychopharmacology_1999.pdf	113685	no	6
			ff29ac4ea9e0f7ca93c6fc8c6690a8c9a07aba2f		
Warnings:					
Information:					

16	NPL Documents	13Fox_JPharmExpTher_2005.pdf	918938 23776d06233c9ce9ae0a42aa260754229e82a9c7	no	15
Warnings:					
Information:					
17	NPL Documents	14Wijtman_ExpOpinionInvest Drugs_2007.pdf	325360 6efd7361cf4904286b377982f837936b4fdd368	no	20
Warnings:					
Information:					
18	NPL Documents	15Celanire_DDT_2005.pdf	361602 e40783475c4f20604295a60901e92ee1ddc47b70	no	15
Warnings:					
Information:					
19	NPL Documents	16Sander_BioPharmBull_2008.pdf	2446624 b868aa42a2c6e96bf82636f144056117abf88c31	no	19
Warnings:					
Information:					
20	Fee Worksheet (PTO-875)	fee-info.pdf	30845 76137696946675ad9488c1fd2123d4ea1a6781ed	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			56500522		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					